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Background—The use of drug-eluting stents (DESs) versus bare metal stents (BMSs) in primary percutaneous coronary
intervention (PCI) for ST-segment elevation myocardial infarction is a matter of debate. Therefore, we examined the risk
of target lesion revascularization (TLR), stent thrombosis, myocardial infarction, and death after the implantation of
DES or BMS in primary PCI patients in Western Denmark.
Methods and Results—A total of 3756 consecutive patients with ST-segment elevation myocardial infarction treated with
primary PCI and stent implantation, recorded in the Western Denmark Heart Registry from January 2002 through June
2005, were followed up for 2 years. We used Cox regression analysis to control for confounding. The 2-year incidence
of definite stent thrombosis was 1.9% in the DES group and 1.1% in the BMS group (adjusted relative risk [RR]1.53;
95% CI0.84 to 2.78; P0.17). Very late definite stent thrombosis (12 months) was seen in 0.4% in the DES group
and 0.06% in the BMS group (adjusted RR6.74; 95% CI1.23 to 37.00; P0.03). The 2-year incidence of myocardial
infarction was similar in the 2 groups, 5.2% in the DES group versus 6.3% in the BMS group (P0.28; adjusted
RR1.13; 95% CI0.81 to 1.59; P0.47). All-cause 2-year mortality was 7.8% in the DES group and 11.4% in BMS
group (P0.004; adjusted RR0.79; 95% CI0.60 to 1.04; P0.09). The 2-year incidence of target lesion
revascularization was 7.2% in the DES group and 8.7% in the BMS group (P0.09; adjusted RR0.70; 95% CI0.52
to 0.92; P0.012).
Conclusions—In ST-segment elevation myocardial infarction patients treated with primary PCI, target lesion revascular-
ization was reduced by 30% in patients treated with a DES. The risk of very late definite stent thrombosis was low but
increased in patients treated with DES. DES was not associated with increased risk of myocardial infarction or death,
when compared with BMS. (Circ Cardiovasc Intervent. 2008;1:176-184.)
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Primary percutaneous coronary intervention (PCI) is awell-established treatment for ST-segment elevation
myocardial infarction (STEMI).1,2 Drug-eluting stents
(DESs) were developed to address the problem of in-stent
restenosis in patients who underwent bare metal stent (BMS)
implantation. Randomized trials have shown that sirolimus-
eluting stents are superior to BMS in STEMI patients in
reducing the incidence of restenosis and target lesion revas-
cularization (TLR).3–5 The beneficial effects of paclitaxel-
eluting stents in STEMI patients are less well documented,
with only 1 randomized trial showing a trend toward better
outcome with paclitaxel-eluting stents.6
The long-term beneficial effects of DES have been ques-
tioned by reports of increased risks of stent thrombosis,7
myocardial infarction (MI), and death.8–10 However, these
possible safety problems were not confirmed in other stud-
ies.10,11 For STEMI patients treated with primary PCI, data on
long-term outcomes after DES implantation are limited. A
clinical database study of a relatively small STEMI patient
cohort detected an initial beneficial effect that disappeared
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over time. After 3 years of follow-up, the initial significantly
lower target vessel revascularization rate in this group disap-
peared, and an increased rate of stent thrombosis was ob-
served in the DES group (BMS, 1.6%; sirolimus-eluting stent,
2.7%; and paclitaxel-eluting stent, 2.9%).12 The current study
assessed the use of DES versus BMS in a large cohort of
primary PCI patients who received dual antiplatelet therapy
for 12 months in accordance with recent recommendations.
We used data from the Western Denmark Heart Registry
(WDHR) to examine the rates of stent thrombosis, MI, death,
and TLR after the implantation of DES or BMS in STEMI
patients treated with primary PCI.
Methods
Setting and Design
The study was conducted using Western Denmark’s health care
databases, which cover the entire population of the region of 3.0
million inhabitants (55% of the Danish population). All patients were
followed-up for 24 months. A detailed description of the databases
has been reported previously.10
Patients and Procedures
Primary PCI for STEMI has been the recommended treatment in
Denmark after the publication of the DANish trial in Acute Myo-
cardial Infarction-2 (DANAMI-2)1 study in 2003. To be eligible for
primary PCI, patients must meet the following criteria: (1) symptoms
present 12 hours from onset of pain to time of catheterization, and
(2) ST-segment elevation (at least 1 mm in 2 or more standard leads
or at least 2 mm in 2 or more contiguous precordial leads) or a new
left bundle-branch block. We used the WDHR to identify all primary
PCIs performed from January 1, 2002 through June 30, 2005. For
inclusion in the current study, patients had to receive either DES or
BMS. Those treated with balloon angioplasty without stent implan-
tation or with a combination of BMS and DES were excluded (n91;
2.4%). During the first year of the study, only BMS were available.
From 2003, DES or BMS was selected according to the preference of
the PCI operator. PCI was performed according to the standard
practices of the participating centers. A glycoprotein IIb/IIIa receptor
blocker was administered at the operator’s discretion. The postint-
ervention antiplatelet regimen included lifelong acetylsalicylic acid
(75 to 150 mg once daily) and clopidogrel with a loading dose of 300
mg followed by maintenance with 75 mg daily. The recommended
duration of clopidogrel treatment was 3 to 12 months until November
2002 and 12 months thereafter. In patients with definite stent
thrombosis, medical records were reviewed to document the use of
antiplatelet therapy.
End Points
The end points were the time to stent thrombosis (definite, probable,
and possible), MI, all-cause mortality, cardiac death, and TLR. All
end points were assessed within 24 months of the PCI date and
ascertained from the WDHR, the Danish National Patient Registry
(NPR) covering all Danish hospitals and the Danish Registry of
Causes of Death. All patients were followed-up for 24 months.
Stent Thrombosis
We defined stent thrombosis using the Academic Research
Consortium’s definition, with a modification for probable stent
thrombosis.13
Definite Stent Thrombosis
Angiographic confirmation of stent thrombosis and at least 1 of the
following signs present within 48 hours: new onset of ischemic
symptoms at rest, new electrocardiographic changes suggestive of
acute ischemia, or typical increase and decrease of cardiac
biomarkers.
Probable Stent Thrombosis
Any unexplained death within the first 30 days after intracoronary
stenting.
Possible Stent Thrombosis
Any unexplained death occurring from 30 days after intracoronary
stenting until the end of the follow-up period. Stent thrombosis was
further characterized as acute (0 to 24 hours), subacute (1 day to
30 days), late (30 days to 1 year), and very late (1 year to 24
months).
We defined new MIs as hospitalization for MI occurring28 days
after the index PCI.14 We ascertained admissions and readmissions
for MI (ICD-10 codes I21-I21.9) from the Danish National Patient
Registry10 and deaths from the Civil Registration System. We
validated the recorded cause of death using original death certificates
obtained from the National Registry of Causes of Death and
classified deaths according to their underlying cause.
From the WDHR, we ascertained TLR, defined as a repeat PCI of
the index lesion or coronary artery bypass grafting, occurring within
2 years after the index stent implantation. We assessed all clinical
end points occurring within 2 years of the index PCI. An expert
committee reviewed relevant records and adjudicated the end points
regarding stent thrombosis and cause of death. For all cases of stent
thrombosis, we reviewed relevant medical records and catheteriza-
tion films.
Covariates
From the WDHR, we retrieved data on potential predictors for
subsequent cardiovascular events, including the characteristics of the
patients, procedures, and lesions. For each patient, we obtained data
on all discharge diagnoses from the Danish National Patient Regis-
try. We then computed the comorbidity scores using the Charlson
comorbidity index,15 which covers 19 major disease categories,
including diabetes mellitus, heart failure, cerebrovascular diseases,
and cancer. The index value is a weighted summary of the diagnoses,
with each weight calculated based on 1-year mortality associated
with each disease in the original Charlson dataset.15
Data on all key patient and procedure characteristics were 95%
complete, and ascertainment of end points (stent thrombosis, death,
MI, and TLR) was 100% complete.
Statistical Methods
Distributions of continuous variables in the 2 groups were compared
using either the 2-sample t test or the Mann–Whitney test, depending
on whether the data followed the normal distribution. Continuous
variables are presented either as median and interquartile range (25th
to 75th) or mean1 SD depending on whether the data followed the
normal distribution or not. Distributions of categorical variables
were compared using the 2 test.
We counted end point events that occurred during the follow-up
period and compared their rates for the cohort of patients with DES
and the cohort with BMS. Follow-up began on the date of the index
PCI procedure. In analyses with stent thrombosis as the outcome,
follow-up continued until date of definite stent thrombosis, death,
emigration, or until 24 months after implantation, whichever came
first. In analyses with death as the outcome, follow-up continued
until date of death, emigration or until 24 months after implantation.
In analyses with MI as the outcome, follow-up continued until date
of MI, death, emigration, or until 24 months after implantation.
We constructed Kaplan–Meier curves for patients and lesions
treated with DES or BMS and used the life-table method to compute
the 2-year incidence for each end point (proportion of the population
at risk with the outcome of interest). Cox proportional-hazards
regression was used to compute hazard ratios as estimates of the
relative risk (RR) for each end point. Because the hazards were not
proportional throughout the follow-up period, we computed the
estimates of RR within separate time windows, where the propor-
tionality assumption held. The RR in these analyses reflected the risk
among patients alive and at risk of the specific end point at the start
of each time period (eg, after 30 days or 1 year of follow-up). We
controlled for age, gender, diabetes mellitus, and procedure time in
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all regression analyses. To improve precision of the risk estimates,
we used the change-in-estimate method, which entailed retaining
variables that changed RR estimates for an outcome by 10%.16
Thus, in the lesion-specific analyses (stent thrombosis and TLR) we
also adjusted for glycoprotein IIb/IIIa receptor blockers, stent length,
and reference vessel size. We also carried out Cox regression based
on propensity score estimated. The latter was estimated by logistic
regression as predicted probability of use of BMSs as a function of
all measured potential confounding factors.17 All data analyses were
carried out using the SAS software version 9.13 (SAS Institute Inc).
Results
Descriptive Data
A total of 3756 STEMI patients (4469 lesions) treated with
primary PCI and stenting were followed up for 24 months. Of
these, 2973 patients with 3486 lesions were treated with
BMS, whereas 783 patients with 983 lesions received DES.
The number of patients treated with DES was 783 (Cypher
stent: n465 [59.4%], Taxus stent: n318 [40.6%]), and
those treated with BMS was 2973. The patients’ median age
was 63 years (interquartile range, 54 to 73 years), and 30.9%
of patients were older than 75 years. Baseline patient and
procedure characteristics (Table 1) and lesion characteristics




The 2-year incidence of definite stent thrombosis did not
differ significantly between patients treated with DES (n19;
1.9%) and BMS (n38; 1.1%; adjusted RR1.53; 95%
CI0.84 to 2.78; P0.17). Definite stent thrombosis oc-
curred within a week in 34 lesions (60%; DES, 0.9% [n9];
and BMS, 0.7% [n25]) and within 30 days in 42 lesions
(74%; DES, 1.2% [n12]; and BMS, 0.9% [n30]). Median
time to occurrence of definite stent thrombosis was 5 days
(interquartile range, 1 to 37 days). Rates of acute, subacute,
and late definite stent thrombosis were also similar in the 2
groups (Figure 1A). The cumulative incidence of stent
thrombosis over time showed an initial steep rise, followed by
an almost linear slight increase up to 24 months. Very late
definite stent thrombosis occurred in 4 lesions (0.4%) in the
DES group and in 2 lesions (0.06%) in the BMS group
(adjusted RR6.74; 95% CI1.23 to 37.00; P0.03; Table
3 and Figure 2A).
Predictors of Definite Stent Thrombosis
Treatment with glycoprotein IIb/IIIa receptor blockers re-
duced the risk of definite stent thrombosis (adjusted
RR0.47; 95% CI0.27 to 0.83; P0.008). Stent length
(adjusted RR1.03; 95% CI1.00 to 1.06; P0.07) and
procedure time (adjusted RR1.01; 95% CI1.00 to 1.02;
P0.12) did not influence the risk of definite stent thrombo-
sis significantly. Neither infarct-related artery nor TIMI flow
before intervention (adjusted RR0.72; 95% CI0.36 to
1.56; P0.37) and TIMI flow after intervention (adjusted
RR1.52; 95% CI0.54 to 4.25; P0.42) were related to
risk of stent thrombosis.
Definite, Probable, or Possible Stent Thrombosis
Definite, probable, or possible stent thrombosis was found in
28 patients treated with DES (2-year incidence, 3.6%) and in
106 patients treated with BMS (2-year incidence, 3.6%;
RR0.99; 95% CI0.65 to 1.50; P0.96; Figure 1B). After
controlling for covariates, the risk of stent thrombosis (defi-
nite, probable, or possible) did not differ between the 2
groups (adjusted RR1.09; 95% CI0.71 to 1.67; P0.68;
Table 4 and Figure 2B).
Definite Stent Thrombosis and Antiplatelet Therapy
Among the 57 patients who developed definite stent throm-
bosis, 82.5% (n47) were receiving dual antiplatelet therapy
(aspirin and clopidogrel) at the time of the thrombotic event.
In the 6 patients with very late stent thrombosis, 1 patient was
on dual antiplatelet therapy (DES1), 1 patient was treated
with aspirin only (DES1), and 4 patients (DES2 and
BMS2) had discontinued both aspirin and clopidogrel after
12 months.
Mortality
All-cause 2-year mortality was lower in DES than in BMS
patients (7.8% versus 11.4%; P0.004; RR0.67; 95%
CI0.51 to 0.88; P0.0039; Figure 1C). This difference was
not statistically significant after adjustment for covariates
(adjusted RR, 0.79; 95% CI0.60 to 1.04; P0.09; Figure
2C). All-cause mortality 12 to 24 months after initial stenting
was similar in the 2 groups (2.2% versus 2.4%; P0.75;
adjusted RR1.04; 95% CI0.59 to 1.83; P0.90).
Cardiac mortality during the first 30 days was 4.6%, lower
in the DES group (3.2%) than in the BMS group (4.9%)
(P0.039; RR0.65; 95% CI0.43 to 0.98; P0.04). After
adjustment, risk of cardiac death during the first 30 days no
longer differed significantly between the 2 groups (adjusted
RR0.77; 95% CI0.50 to 1.18; P0.23). Cardiac mortality
Table 1. Characteristics of Patients With STEMI Treated With
Primary PCI and DES or BMS in Western Denmark from
January 2002 Through June 2005
DES BMS P
No. of patients 783 2973
Male, n (%) 573 (73.2) 2179 (73.3) 0.95
Age, years (interquartile range) 60.0 (50–69) 64 (55–73) 0.0001
Family history, n (%) 236 (30.1) 812 (27.3) 0.19
Smoking, n (%) 359 (45.9) 1268 (42.7) 0.10
Diabetes mellitus, n (%) 88 (11.2) 240 (8.1) 0.0001
Hypertension, n (%) 169 (21.6) 657 (22.1) 0.23
Previous coronary artery bypass
grafting, n (%)
18 (2.3) 34 (1.1) 0.001
Previous percutaneous coronary
intervention, n (%)
35 (4.5) 118 (4.0) 0.03
Previous MI, n (%) 67 (8.6) 341 (11.5) 0.007
Lipid lowering therapy, n (%) 116 (14.8) 317 (10.7) 0.0006
Glycoprotein IIb/IIIa receptor
blocker, n (%)
514 (65.6) 1717 (57.8) 0.0001
Comorbidity index score, n (%) 0.40
0 547 (70.0) 2004 (67.4)
1–2 190 (24.3) 790 (26.6)
3 46 (5.9) 179 (6.0)
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after 2 years was 6.6%, with lower cardiac mortality among
DES patients than among BMS patients (5.0% versus 7.0%;
P0.037; RR0.70; 95% CI0.50 to 0.99; P0.04). After
adjustment, risk of cardiac death did not differ significantly
between the 2 groups (adjusted RR0.83; 95% CI0.59 to
1.18; P0.31).
Noncardiac 2-year mortality was 3.3%, which was similar
in DES-treated (2.6%) and BMS-treated (3.5%) patients
(RR0.70; 95% CI0.44 to 1.13; P0.15). Controlling for
covariates did not change this result (adjusted RR0.82; 95%
CI0.51 to 1.33; P0.42).
During the second half of the follow-up period (12 to 24
months), after discontinuation of the recommended dual
antiplatelet therapy, neither all-cause mortality, nor cardiac
mortality, nor noncardiac mortality differed between patients
treated with DES or with BMS (Table 4).
Myocardial Infarction
The 2-year incidence of MI was similar in the 2 stent groups
(6.0% in the DES group versus 4.9% in the BMS group;
P0.28 [Figure 1D]; adjusted RR1.13; 95% CI0.81 to
1.59; P0.47 [Figure 2D]).
Target Lesion Revascularization
TLR within 2 years occurred slightly less frequently in DES
patients than in BMS patients (2-year incidence, 7.2% versus
8.7%; P0.09; Figure 1E). After controlling for age, gender,
diabetes mellitus, stent length, reference vessel size, and
glycoprotein IIb/IIIa, the risk reduction with DES was 30%
(adjusted RR0.70; 95% CI0.52 to 0.92; P0.012; Figure
2E). Diabetes mellitus (RR1.66; 95% CI1.19 to 2.31;
P0.003) and stent length (RR [per 1 mm]1.02; 95%
CI1.00 to 1.03; P0.01) increased the risk of TLR within
24 months. Reference vessel size was inversely related to
TLR (RR [per 1 mm]0.82; 95% CI0.67 to 1.00; P0.05).
Propensity Score Analysis
The estimates of effect were unchanged when we used Cox
regression with adjustment for propensity score (calculated
by logistic regression as predicted probability of use of BMSs
Table 2. Procedure Characteristics of Patients With STEMI Treated With Primary
PCI and DES and BMS in Western Denmark, January 2002 Through June 2005
DES BMS P
No. of lesions 983 3,486
Infarct-related artery, n (%) 0.001
Left anterior descending artery, n (%) 607 (61.8) 1341 (38.5)
Left circumflex artery, n (%) 111 (11.3) 505 (14.5)
Right coronary artery, n (%) 235 (23.9) 1607 (46.1)
Left main, n (%) 30 (3.1) 32 (0.9)
Preintervention TIMI flow, n (%) 0.0001
Grade 0 475 (50.3) 1901 (55.7)
Grade 1 52 (5.5) 210 (6.2)
Grade 2 126 (13.4) 459 (13.4)
Grade 3 291 (30.8) 845 (24.7)
Lesion length, mm 15.0 (10.0–20.0) 13.0 (10.0–18.0) 0.0001
Reference segment, mm 3.3 (3.0–3.6) 3.5 (3.0–3.8) 0.0001
Minimum lumen diameter, mm 0 (0–0.30) 0 (0–0.20) 0.002
Stenosis, % of luminal diameter 100 (90–100) 100 (95–100) 0.001
Stent length, mm 18.0 (13.0–24.0) 18.0 (13.0–21.0) 0.0001
Stent, n (%) 0.01
1 790 (80.4) 2,892 (83.3)
2 155 (15.8) 482 (13.9)
3 38 (3.9) 97 (2.8)
Max balloon pressure, atm 15.0 (14.0–18.0) 14.0 (12.0–17.0) 0.0001
Max balloon diameter, mm 3.3 (3.0–3.7) 3.6 (3.2–3.9) 0.0001
Final TIMI flow, n (%) 0.0795
Grade 0 12 (1.3) 32 (0.9)
Grade 1 8 (0.9) 32 (0.9)
Grade 2 44 (4.7) 258 (7.6)
Grade 3 881 (93.3) 3090 (90.5)
Procedure time, min 25.0 (15.0–38.0) 24.0 (15.0–35.0) 0.002
Flouro time, min 8.0 (5.0–13.0) 7.0 (4.0–11.3) 0.0001
Contrast, mL 136.0 (100.0–200.0) 120.0 (82.0–200.0) 0.0001
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Figure 1. A, Risk of definite stent thrombosis among patients treated with DES or BMS. B, Risk of definite, probable, and possible
stent thrombosis among patients treated with DES or BMS. C, All-cause mortality among patients treated with DES or BMS. D, Risk of
MI among patients treated with DES or BMS. E, TLR among patients treated with DES or BMS (unadjusted data).
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given measured potential confounding factors). Patients with
DES and BMS did not significantly differ with respect to
their risk of definite stent thrombosis (adjusted RR1.88;
95% CI0.95 to 3.72). Very late definite stent thrombosis
was seen more often in DES treated patients (adjusted
RR6.51; 95% CI1.19 to 35.70). All-cause 2-year mortal-
ity (adjusted RR0.67; 95% CI0.50 to 0.91) and cardiac
mortality (adjusted RR0.67; 95% CI0.46 to 0.98) were
lower in DES treated patients. The 2-year incidence of MI
was similar in the 2 stent groups (adjusted RR1.31; 95%
CI0.88 to 1.95).
Discussion
The current study shows that primary PCI patients treated
with either DES or BMS in a real-world setting have similar
2-year risks of stent thrombosis, MI, or death. Within the
same period, the use of DES was associated with 30%
reduction in the risk of clinically driven TLR. To our
knowledge, our study represents the largest published data-
base of STEMI patients treated with primary PCI. The 3
interventional centers in our study are all high-volume PCI
centers, and one third of the PCI procedures are primary PCI
including optimized transportation logistics.1
An important clinical dilemma exists as to whether the
benefit of reduced repeat revascularization with DES out-
weighs the harm of a possible increased risk of the rare but
serious complication of late stent thrombosis. Another con-
cern is whether the net TLR reduction after DES is main-
tained during longer-term follow-up, especially after cessa-
tion of dual antiplatelet therapy. Our data show that 25% of
definite stent thromboses occurred acutely within 24 hours
and that another 50% occurred within 30 days. During these
first 30 days, the risk of definite stent thrombosis was similar
in patients treated with DES or BMS. Previous studies on
BMS implanted during primary PCI for MI have found high
thrombosis rates. However, this is limited by the absence of
a uniform definition for stent thrombosis in these studies.
Current studies comparing DES and BMS in this setting have
also found high rates of stent thrombosis in both groups. Stent
thrombosis is therefore more frequent in primary PCI for
acute MI compared with planned procedures and the rates of
stent thrombosis are similar for DES and BMS. However,
longer follow-up is necessary to follow the risk of very late
stent thrombosis to ensure that this risk will not outweigh the
benefit with reduction in TLR.
Several factors are associated with an increased risk of
stent thrombosis in STEMI patients treated with primary PCI,
including the risk of incomplete stent apposition18 or under-
expansion of the stent itself.19 Further, the increased platelet
activation in acute MI,20 coupled with delayed healing, risk
of lack of endothelialization, and exposure to proinflam-
matory and thrombogenic environment, might explain the
increased risk of stent thrombosis in STEMI patients.21
However, neither in our study nor in the 3 randomized studies
(TYPHOON,4 PASSION,6 and SESAMI3) did these possible
pathophysiological processes result in an increased risk of
early stent thrombosis after DES implantation. In the current
study, definite stent thrombosis during the first year after the
cessation of dual antiplatelet therapy was more common after
DES than after BMS treatment. This difference, although it
was extremely small, is still important. At the same time,
DES was associated with a marked and persistent reduction
in TLR.
Another important finding in our study is the significantly
lower risk of definite stent thrombosis in patients treated with
a glycoprotein IIb/IIIa receptor blocker. In the CADILLAC
trial,22 subacute thrombosis was reduced by 74% in patients
treated with abciximab. However, abciximab treatment did
not affect the composite end point at 1 year. Although the
glycoprotein IIb/IIIa receptor blocker treatment in our study
was administered at the discretion of the PCI operator, we
observed a similar risk reduction of 53% in definite stent
thrombosis after glycoprotein IIb/IIIa receptor blocker ad-
ministration compared with abciximab administration. In the
STRATEGY trial,23 patients treated with DES plus tirofiban
had less angiographic stent thrombosis at 30 days compared
with patients treated with the combination of BMS plus
abciximab (0 versus 3 stent thromboses). In the recently
published MULTISTRATEGY trial,24 tirofiban therapy,
when compared with abciximab, was associated with nonin-
ferior resolution of ST-segment elevation at 90 minutes after
coronary intervention, whereas sirolimus-eluting stent im-
plantation was associated with a significantly lower than
uncoated stents risk of major adverse cardiac events within 8
months after intervention. The ADMIRAL study25 did not
present data on stent thrombosis, but it demonstrated that
early inhibition of the platelet glycoprotein (GP) IIb/IIIa
receptor with abciximab led to improved coronary patency,
left ventricular function, and better clinical outcomes. Long-
term follow-up in the ADMIRAL study25,26 showed that
adjunctive abciximab to primary stenting for STEMI elicits
Table 3. Risk of Definite Stent Thrombosis in Patients With STEMI Treated With Primary PCI and DES (n983) or BMS
(n3486) in Western Denmark
DES BMS
RR* (95% CI) PNo. of Events No./100 Person-Year No. of Events No./100 Person-Year
All 19 1.05 38 0.61 1.53 (0.84–2.78) 0.17
Acute (24 h) 5 187.7 9 95.9 1.56 (0.48–5.09) 0.46
1 day to 30 days 7 9.1 21 7.8 1.04 (0.41–2.60) 0.94
30 days to 12 months 3 0.4 6 0.2 1.36 (0.26–7.03) 0.72
12 months 4 0.5 2 0.1 6.74 (1.23–37.0) 0.03
*Adjusted for age, sex, diabetes mellitus, stent length, reference vessel size, procedure time, and glycoprotein IIb/IIIa.
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Figure 2. A, Risk of definite stent thrombosis among patients treated with DES or BMS. B, Risk of definite, probable, and possible
stent thrombosis among patients treated with DES or BMS. C, All-cause mortality among patients treated with DES or BMS. D, Risk of
MI among patients treated with DES or BMS. E, TLR among patients treated with DES or BMS (adjusted data).
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favorable clinical outcomes with the same absolute reduc-
tions in risks of “hard” clinical outcomes from 30 days up to
3 years of follow-up.
Mortality in the current study was generally higher for
patients treated with DES or BMS compared with mortality
estimates reported in both a meta-analysis27 and in random-
ized clinical trials of DES versus BMS in primary PCI.3–6
This may be important for the interpretation of our data,
because randomized trials (and the meta-analysis based on
these trials) usually include highly selected patients. Thus,
our study extends the results of the randomized trials to a
real-world setting. Clinically driven TLR was lower in our
study than in the randomized trials, probably because routine
angiographic follow-up in such trials increases the TLR rate.
The current data did not demonstrate significant differ-
ences in the cumulative rates of death or MI after 2 years for
patients treated with DES or BMS. Furthermore, all-cause
mortality and cardiac mortality for patients treated with
primary PCI were similar to the findings in the DANAMI-2
study.28
Limitations
The validity of our findings depends on data quality and the
ability to control for potential confounding. Our design is
based on computerized registries with complete nationwide
coverage, enabling study of a well-defined large population
with complete follow-up. However, like all observational
studies, our study is prone to biases related to unmeasured
factors. A bias attributable to an unknown variable cannot be
eliminated.
We collected data over a 3-year period, during which the
prevalence of DES stents implanted increased from zero to
53%. To reduce bias during this transition period, we
followed-up every patient for up to 24 months. It also is
important to note that although we report 12 months as the
recommended duration of dual antiplatelet treatment, we had
only access to the actual duration of this treatment among
patients with definite stent thrombosis. Finally, according to
the ARC definition of probable and possible stent thrombosis,
we categorized all unexplained deaths as stent thromboses.
However, it is unlikely that stent thrombosis was the cause of
death in all cases of unexplained death.
Conclusions
The results of the current study indicated that patients treated
with stent implantation during primary PCI the overall rates
of stent thrombosis, MI, and death were of similar magnitude
in patients receiving DES or BMS after 2 years. Compared
with BMS, DES improved the clinical outcome by reducing
the risk of clinically driven TLR.
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